Cargando…
Update Overview of the Role of Angiopoietins in Lung Cancer
Angiogenesis is a biological process that involves the formation of new blood vessels from the existing vasculature, and it plays a fundamental role in the development and progression of several types of cancer, including lung cancer. The angiopoietin/Tie2 ligand/receptor system orchestrates vascula...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625006/ https://www.ncbi.nlm.nih.gov/pubmed/34833409 http://dx.doi.org/10.3390/medicina57111191 |
_version_ | 1784606312403828736 |
---|---|
author | Tsakogiannis, Dimitris Nikolakopoulou, Asimina Zagouri, Flora Stratakos, Grigorios Syrigos, Konstantinos Zografos, Eleni Koulouris, Nikolaos Bletsa, Garyfalia |
author_facet | Tsakogiannis, Dimitris Nikolakopoulou, Asimina Zagouri, Flora Stratakos, Grigorios Syrigos, Konstantinos Zografos, Eleni Koulouris, Nikolaos Bletsa, Garyfalia |
author_sort | Tsakogiannis, Dimitris |
collection | PubMed |
description | Angiogenesis is a biological process that involves the formation of new blood vessels from the existing vasculature, and it plays a fundamental role in the development and progression of several types of cancer, including lung cancer. The angiopoietin/Tie2 ligand/receptor system orchestrates vascular integrity. In particular, Angiopoietin-1 activates the endothelial cell (EC)-specific receptor tyrosine kinase, Tie2, which is essential for preserving endothelial quiescence. On the other hand, Angiopoietin-2 acts as an inhibitor of the Angiopoietin-1/Tie2 signaling pathways, thus facilitating the destabilization of quiescent endothelium in cases of inflammation and cancer. Clinical studies have proven that high levels of Angiopoietin-2 indicate the development of non-small-cell lung carcinomas (NSCLC), while high levels of Angiopoietin-2 are strongly related to tumor angiogenesis, lymphangiogenesis, metastasis, and poor prognosis. Interestingly, the association of Angiopoietin-2 levels with the type of surgical approach makes Angiopoietin-2 a valuable factor in selecting the most suitable therapeutic strategy for lung cancer patients. The role of the Angiopoietin-1 and Angiopoietin-4 levels in NSCLC development requires further investigation. The present review focuses on the clinical impact of the Angiopoietin-1, Angiopoietin-2, and Angiopoietin-4 levels in patients diagnosed with NSCLC, emphasizing the interaction between them, and how they affect the development, progression, and metastasis of lung disease. Finally, it estimates the role of angiopoietins levels in the effective therapy of lung cancer patients. |
format | Online Article Text |
id | pubmed-8625006 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86250062021-11-27 Update Overview of the Role of Angiopoietins in Lung Cancer Tsakogiannis, Dimitris Nikolakopoulou, Asimina Zagouri, Flora Stratakos, Grigorios Syrigos, Konstantinos Zografos, Eleni Koulouris, Nikolaos Bletsa, Garyfalia Medicina (Kaunas) Review Angiogenesis is a biological process that involves the formation of new blood vessels from the existing vasculature, and it plays a fundamental role in the development and progression of several types of cancer, including lung cancer. The angiopoietin/Tie2 ligand/receptor system orchestrates vascular integrity. In particular, Angiopoietin-1 activates the endothelial cell (EC)-specific receptor tyrosine kinase, Tie2, which is essential for preserving endothelial quiescence. On the other hand, Angiopoietin-2 acts as an inhibitor of the Angiopoietin-1/Tie2 signaling pathways, thus facilitating the destabilization of quiescent endothelium in cases of inflammation and cancer. Clinical studies have proven that high levels of Angiopoietin-2 indicate the development of non-small-cell lung carcinomas (NSCLC), while high levels of Angiopoietin-2 are strongly related to tumor angiogenesis, lymphangiogenesis, metastasis, and poor prognosis. Interestingly, the association of Angiopoietin-2 levels with the type of surgical approach makes Angiopoietin-2 a valuable factor in selecting the most suitable therapeutic strategy for lung cancer patients. The role of the Angiopoietin-1 and Angiopoietin-4 levels in NSCLC development requires further investigation. The present review focuses on the clinical impact of the Angiopoietin-1, Angiopoietin-2, and Angiopoietin-4 levels in patients diagnosed with NSCLC, emphasizing the interaction between them, and how they affect the development, progression, and metastasis of lung disease. Finally, it estimates the role of angiopoietins levels in the effective therapy of lung cancer patients. MDPI 2021-11-01 /pmc/articles/PMC8625006/ /pubmed/34833409 http://dx.doi.org/10.3390/medicina57111191 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tsakogiannis, Dimitris Nikolakopoulou, Asimina Zagouri, Flora Stratakos, Grigorios Syrigos, Konstantinos Zografos, Eleni Koulouris, Nikolaos Bletsa, Garyfalia Update Overview of the Role of Angiopoietins in Lung Cancer |
title | Update Overview of the Role of Angiopoietins in Lung Cancer |
title_full | Update Overview of the Role of Angiopoietins in Lung Cancer |
title_fullStr | Update Overview of the Role of Angiopoietins in Lung Cancer |
title_full_unstemmed | Update Overview of the Role of Angiopoietins in Lung Cancer |
title_short | Update Overview of the Role of Angiopoietins in Lung Cancer |
title_sort | update overview of the role of angiopoietins in lung cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625006/ https://www.ncbi.nlm.nih.gov/pubmed/34833409 http://dx.doi.org/10.3390/medicina57111191 |
work_keys_str_mv | AT tsakogiannisdimitris updateoverviewoftheroleofangiopoietinsinlungcancer AT nikolakopoulouasimina updateoverviewoftheroleofangiopoietinsinlungcancer AT zagouriflora updateoverviewoftheroleofangiopoietinsinlungcancer AT stratakosgrigorios updateoverviewoftheroleofangiopoietinsinlungcancer AT syrigoskonstantinos updateoverviewoftheroleofangiopoietinsinlungcancer AT zografoseleni updateoverviewoftheroleofangiopoietinsinlungcancer AT koulourisnikolaos updateoverviewoftheroleofangiopoietinsinlungcancer AT bletsagaryfalia updateoverviewoftheroleofangiopoietinsinlungcancer |